Skip to main content

Advertisement

SpringerLink
Log in

Systemic Disease and Portal Hypertension

  • Review
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The development of portal hypertension is typically a consequence of liver cirrhosis due mainly to primary liver disorders, whereas non-cirrhotic portal hypertension (NCPH) can be a complication of systemic, primarily extrahepatic diseases. Our purpose was to review the various systemic disorders leading to portal hypertension and provide a pathway for diagnosis and management.

Recent Findings

Non-cirrhotic portal hypertension is a heterogeneous group of liver disorders primarily of vascular origin that may manifest as portal hypertension. The diagnosis of NCPH in the setting of systemic diseases is challenging and a liver biopsy may be required to confirm the diagnosis. Etiologies include those of vascular origin, autoimmune disorders, drug exposures, and infections.

Summary

Complications of portal hypertension in the setting of systemic diseases are similar to patients having cirrhosis and should be addressed similarly while addressing the underlying systemic disorder if possible

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011;54(3):1071–81.

    Article  PubMed  Google Scholar 

  2. Gracia-Sancho J, Marrone G, Fernández-Iglesias A. Hepatic microcirculation and mechanisms of portal hypertension. Nat Rev Gastroenterol Hepatol. 2019;16(4):221–34.

    Article  PubMed  Google Scholar 

  3. Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology. 2019;156(6).

  4. Simonetto DA, Liu M, Kamath PS. Portal hypertension and related complications :diagnosis and management. Mayo Clin Proc. 2019;94(4):714–26.

    Article  PubMed  Google Scholar 

  5. Khanna R, Sarin SK. Idiopathic portal hypertension and extrahepatic portal venous obstruction. Hepatol Int. 2018;12(Suppl 1):148–67.

    Article  PubMed  Google Scholar 

  6. Da BL, Surana P, Kapuria D, Vittal A, Levy E, Kleiner DE, Koh C, Heller T. Portal pressure in noncirrhotic portal hypertension: to measure or not to measure. Hepatology. 2019;70(6):2228–30. Of major importance: This study reported in a large cohort of individuals with non-cirrhotic portal hypertension that portal pressures as assessed by HVPH are not typically elevated and also do not correlate with complications of portal hypertension. They suggest that at obtaining a liver biopsy percutaneously may be an appropriate strategy in this population.

    Article  PubMed  Google Scholar 

  7. Eapen CE, Nightingale P, Hubscher SG, et al. Non-cirrhotic intrahepatic portal hypertension: associated gut diseases and prognostic factors. Dig Dis Sci. 2011;56(1):227–35.

    Article  CAS  PubMed  Google Scholar 

  8. Sharma P, Agarwal R, Dhawan S, Bansal N, Singla V, Kumar A, Arora A. Transient elastography (fibroscan) in patients with non-cirrhotic portal fibrosis. J Clin Exp Hepatol. 2017;7(3):230–4.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Sarin SK, Khanna R. Noncirrhotic portal hypertension. Clin Liver Dis. 2014;18:451–76.

    Article  PubMed  Google Scholar 

  10. Verheij J, Schouten JN, Komuta M, et al. Histological features in western patients with idiopathic non-cirrhotic portal hypertension. Histopathology. 2013;62(7):1083–91.

    Article  PubMed  Google Scholar 

  11. Lee H, Rehman AU, Fiel MI. Idiopathic noncirrhotic portal hypertension: an appraisal. J Pathol Transl Med. 2016;50(1):17–25.

    Article  PubMed  Google Scholar 

  12. Nayak NC, Jain D, Saigal S, Soin AS. Non-cirrhotic portal fibrosis: one disease with many names? An analysis from morphological study of native explant livers with end stage chronic liver disease. J Clin Pathol. 2011;64(7):592–8.

    Article  PubMed  Google Scholar 

  13. Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the west: a re-evaluation in 28 patients. Gut. 2002;51(2):275–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. De Gottardi A, Rautou PE, Schouten J, Rubbia-Brandt L, Leebeek F, Trebicka J, Murad SD, Vilgrain V, Hernandez-Gea V, Nery F, Plessier A. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol. 2019;4(5):399–411.

    Article  PubMed  Google Scholar 

  15. Cerda Reyes E, González-Navarro EA, Magaz M, Muñoz-Sánchez G, Diaz A, Silva-Junior G, et al. Autoimmune biomarkers in porto-sinusoidal vascular disease: potential role in its diagnosis and pathophysiology. Liver Int. 2021;41(9):2171–8.

    Article  CAS  PubMed  Google Scholar 

  16. Sarin SK, Kapoor D. Non-cirrhotic portal fibrosis: current concepts and management. J Gastroenterol Hepatol. 2002;17:526–34.

    Article  CAS  PubMed  Google Scholar 

  17. Madhu K, Avinash B, Ramakrishna B, Eapen CE, Shyamkumar NK, Zachariah U, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension: common cause of cryptogenic intrahepatic portal hypertension in a Southern Indian tertiary hospital. Indian J Gastroenterol. 2009;28:83–7.

    Article  PubMed  Google Scholar 

  18. Okudaira M, Ohbu M, Okuda K. Idiopathic portal hypertension and its pathology. Semin Liver Dis. 2002;22(1):59–72.

    Article  PubMed  Google Scholar 

  19. Chang P-E, Miquel R, Blanco J-L, Laguno M, Bruguera M, Abraldes JG, et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol. 2009;104:1707–14.

    Article  CAS  PubMed  Google Scholar 

  20. Schouten JN, Van der Ende ME, Koëter T, et al. Risk factors and outcome of HIV associated idiopathic noncirrhotic portal hypertension. Aliment Pharmacol Ther. 2012;36(9):875–85.

    Article  CAS  PubMed  Google Scholar 

  21. Mallet V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H, Lascoux-Combe C, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS. 2007;21:187–92.

    Article  PubMed  Google Scholar 

  22. Okuda K. Non-cirrhotic portal hypertension versus idiopathic portal hypertension. J Gastroenterol Hepatol. 2002;17(Suppl 3):S204–13.

    PubMed  Google Scholar 

  23. Salzer U, Warnatz K, Peter HH. Common variable immunodeficiency: an update. Arthritis Res Ther. 2012;14:223.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Xiao X, Miao Q, Chang C, Gershwin ME, Ma X. Common variable immunodeficiency and autoimmunity—an inconvenient truth. Autoimmun Rev. 2014;13:858–64.

    Article  CAS  PubMed  Google Scholar 

  25. Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena MT, Espinosa-Rosales FJ, et al. International consensus document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4:38–59.

    Article  PubMed  Google Scholar 

  26. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119:1650–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Gathmann B, Mahlaoui N, Gerard L, Oksenhendler E, Warnatz K, Schulze I, Kindle G, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134:116–26.

    Article  PubMed  Google Scholar 

  28. Cunningham-Rundles C, Maglione PJ. Common variable immunodeficiency. J Allergy Clin Immunol. 2012;129:1425-1426.e1423.

    Article  PubMed  Google Scholar 

  29. Fuss IJ, Friend J, Yang Z, et al. Nodular regenerative hyperplasia in common variable immunodeficiency. J Clin Immunol. 2013;33:748–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Inagaki H, Nonami T, Kawagoe T, et al. Idiopathic portal hypertension associated with systemic lupus erythematosus. J Gastroenterol. 2000;35(3):235–9.

    Article  CAS  PubMed  Google Scholar 

  31. van Hoek B. The spectrum of liver disease in systemic lupus erythematosus. Neth J Med. 1996;48(6):244–53.

    Article  PubMed  Google Scholar 

  32. Matsumoto T, Yoshimine T, Shimouchi K, et al. The liver in systemic lupus erythematosus: pathologic analysis of 52 cases and review of Japanese Autopsy Registry Da-ta. Hum Pathology. 1992;23(10):1151–8.

    Article  CAS  Google Scholar 

  33. Efe C, Purnak T, Ozaslan E, et al. Autoimmune liver disease in patients with systemic lupus erythematosus retrospective analysis of 147 cases. Scand J Gastroenterol. 2011;46(6):732–7.

    Article  CAS  PubMed  Google Scholar 

  34. Kraaijvanger R, Janssen Bonás M, Vorselaars AD, Veltkamp M. Biomarkers in the diagnosis and prognosis of sarcoidosis: current use and future prospects. Front Immunol. 2020;14(11):1443.

    Article  Google Scholar 

  35. Kennedy PTF, Zakaria N, Modawi SB, et al. Natural history of hepatic sarcoidosis and its response to treatment. European J Gastroenterol Hepatol. 2006;18:721–6.

    Article  CAS  Google Scholar 

  36. Bodh V, Chawla YK. Noncirrhotic intrahepatic portal hypertension. Clin Liver Dis. 2014;3:129–32.

    Article  Google Scholar 

  37. Koukounari A, Donnelly CA, Sacko M, Keita AD, Landouré A, Dembelé R, et al. The impact of single versus mixed schistosome species infections on liver, spleen and bladder morbidity within Malian children pre- and post-praziquantel treatment. BMC Infect Dis. 2010;10:227.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Mazigo HD, Nuwaha F, Wilson S, Kinung’hi SM, Morona D, Waihenya R, et al. Epidemiology and interactions of human immunodeficiency virus - 1 and Schistosoma Mansoni+ in sub-Saharan Africa. Infect Dis Poverty. 2013;2(1):2.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Pereira TA, Xie G, Choi SS, Syn WK, Voieta I, Lu J, et al. Macrophage-derived hedgehog ligands promotes fibrogenic and angiogenic responses in human Schistosomiasis mansoni. Liver Int. 2013;33:149–61.

    Article  CAS  PubMed  Google Scholar 

  40. Mallet VO, Varthaman A, Lasne D, Viard JP, Gouya H, Borgel D, Lacroix-Desmazes S. et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS. 2009;23(12):1511–1518.

  41. Lafeuillade A, Alessi MC, Poizot-Martin I, Dhiver C, Quilichini R, Aubert L, et al. Protein S deficiency and HIV infection. N Engl J Med. 1991;324:1220.

    Article  CAS  PubMed  Google Scholar 

  42. Siramolpiwat S, Seijo S, Miquel R, et al. Idiopathic portal hypertension: natural history and long-term outcome. Hepatology. 2014;59(6):2276–85.

    Article  PubMed  Google Scholar 

  43. Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India. 1999;12:62–8.

    CAS  PubMed  Google Scholar 

  44. Bryceson A. Visceral leishmaniasis in India. Lancet. 2000;356:1933.

    Article  CAS  PubMed  Google Scholar 

  45. Singh S, Sivakumar R. Recent advances in the diagnosis of leishmaniasis. J Postgrad Med. 2003;49:55–60.

    Article  CAS  PubMed  Google Scholar 

  46. Datta DV, Saha S, Grover SL, Samant A, Singh R, Chakravarti N, et al. Portal hypertension in kalaazar. Gut. 1972;13:147–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Agrawal P, Wali JP, Chopra P. Liver in kala-azar. Indian J Gastroenterol. 1990;9:135–6.

    Google Scholar 

  48. Guevara P, Ramirez JL, Rojas L, Scorza JV, Gonzales N, Anez N. Leishmania braziliensis in blood 30 years after cure. Lancet. 1993;341:1341.

    Article  CAS  PubMed  Google Scholar 

  49. Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Practice Res Clin Gastroenterol. 2010;24(2):157–65.

    Article  CAS  Google Scholar 

  50. Wanless IR, Godwin TA, Allen F, Feder A. Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with an hypothesis on the pathogenesis. Medicine. 1980;59:367–79.

    Article  CAS  PubMed  Google Scholar 

  51. DeLeve LD, Wang X, Kuhlenkamp JF, et al. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology. 1996;23:589–99.

    Article  CAS  PubMed  Google Scholar 

  52. De Vito C, Tyraskis A, Davenport M, Thompson R, Heaton N, Quaglia A. Histopathology of livers in patients with congenital portosystemic shunts (Abernethy malformation): a case series of 22 patients. Virchows Arch. 2018;474(1):47–57.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Baiges A, Turon F, Simón-Talero M, Tasayco S, Bueno J, Zekrini K, et al. Congenital extrahepatic portosystemic shunts (Abernethy malformation): an international observational study. Hepatology. 2019;71(2):658–69.

    Article  PubMed  Google Scholar 

  54. Majumdar A, Delatycki MB, Crowley P, et al. with m. J Hepatol. 2015;63(2):525–7.

    Article  PubMed  Google Scholar 

  55. Besmond C, Valla D, Hubert L, et al. Mutations in the novel gene FOPV are associated with familial autosomal dominant and non-familial obliterative portal venopathy. Liver Int. 2018;38(2):358–64.

    Article  CAS  PubMed  Google Scholar 

  56. Dumortier J, Boillot O, Chevallier M, et al. Familial occurrence of nodular regenerative hyperplasia of the liver: a report on three families. Gut. 1999;45(2):289–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Witters P, Libbrecht L, Roskams T, Boeck KD, Dupont L, Proesmans M, et al. Noncirrhotic pre-sinusoidal portal hypertension is common in cystic fibrosis-associated liver disease. Hepatology. 2011;53:1064–5.

    Article  PubMed  Google Scholar 

  58. Mayer JE, Schiano TD, Fiel MI, Hoffman R, Mascarenhas JO. An association of myeloproliferative neoplasms and obliterative portal venopathy. Dig Dis Sci. 2014;59(7):1638–41.

    Article  PubMed  Google Scholar 

  59. Valla DC, Cazals-Hatem D. Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts. Virchows Arch. 2018;473(1):3–13.

    Article  PubMed  Google Scholar 

  60. Schouten JNL, Nevens F, Hansen B, Laleman W, den Born M, Komuta M, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther. 2012;35:1424–33.

    Article  CAS  PubMed  Google Scholar 

  61. Cazals-Hatem D, Hillaire S, Rudler M, Plessier A, Paradis V, Condat B, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J Hepatol. 2011;54:455–61.

    Article  PubMed  Google Scholar 

  62. Carreras LO, Defreyn G, Machin SJ, Vermylen J, Deman R, Spitz B, et al. Arterial thrombosis, intrauterine death and “lupus” antiocoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet. 1981;1:244–6.

    Article  CAS  PubMed  Google Scholar 

  63. O’Leary JG, Cai J, Freeman R, et al. Proposed diagnostic criteria for chronic antibody mediated rejection in liver allografts. Am J Transpl. 2016;16(2):603–14.

    Article  CAS  Google Scholar 

  64. Etzion O, Koh C, Heller T. Noncirrhotic portal hypertension: An overview. Clin Liver Dis (Hoboken). 2015;6(3):72–74.

  65. Glatard AS, Hillaire S, d’Assignies G, Cazals-Hatem D, Plessier A, Valla DC, Vilgrain V. Obliterative portal venopathy: findings at CT imaging. Radiology. 2012;263(3):741–50.

    Article  PubMed  Google Scholar 

  66. Arora A, Sarin SK. Multimodality imaging of obliterative portal venopathy: what every radiologist should know. Br J Radiol. 2015;88(1046):20140653.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Elkrief L, Lazareth M, Chevret S, Paradis V, Magaz M, Blaise L, Rubbia-Brandt L, et al. Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension. Hepatology. 2020.

  68. Sarin SK, Kumar A, Chawla YK, Baijal SS, Dhiman RK, Jafri W, et al. Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int. 2007.

  69. Dhiman RK, Chawla Y, Vasishta RK, Kakkar N, Dilawari JB, Trehan MS, et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol. 2002;17:6–16.

    Article  PubMed  Google Scholar 

  70. Okuda K, Kono K, Ohnishi K, Kimura K, Omata M, Koen H, et al. Clinical study of eighty-six cases of idiopathic portal hypertension and comparison with cirrhosis with splenomegaly. Gastroenterology. 1984;86:600–10.

    Article  CAS  PubMed  Google Scholar 

  71. Rangari M, Gupta R, Jain M, Malhotra V, Sarin SK. Hepatic dysfunction in patients with extrahepatic portal venous obstruction. Liver Int. 2003;23:434–9.

    Article  CAS  PubMed  Google Scholar 

  72. Bissonnette J, Garcia-Pagán JC, Albillos A, Turon F, Ferreira C, Tellez L, et al. Role of the trans-jugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension: liver failure/cirrhosis/portal hypertension. Hepatology. 2016;64(1):224–31.

    Article  PubMed  Google Scholar 

  73. Lattanzi B, Gioia S, Di Cola S, et al. Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension. Liver Int. 2019;39(10):1937–42. Of major importance: This report notes that the prevalence of sarcopenia in a cohort of patients with non-cirrhotic portal hypertension as assessed by skeletal muscle index (SMI) was similar to those with cirrhosis, decompensated and portal vein thrombosis suggesting that the presence of portal hypertension contributes sarcopenia. In addition, sarcopenia was also associated with a higher rate of variceal bleeding requiring TIPS placement.

    Article  PubMed  Google Scholar 

  74. Dhiman RK, Behera A, Chawla YK, Dilawari JB, Suri S. Portal hypertensive biliopathy. Gut. 2007;56:1001–8.

    Article  PubMed  Google Scholar 

  75. Dilawari JB, Chawla YK. Extrahepatic portal venous obstruction. Gut. 1988;29:L554-555.

    Article  Google Scholar 

  76. Maruyama H, Okugawa H, Kobayashi S, Yoshizumi H, Takahashi M, Ishibashi H, et al. Non-invasive porto-graphy: a microbubble-induced three-dimensional sonogram for discriminating idiopathic portal hypertension from cirrhosis. Br J Radiol. 2012;85(1013):587–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Lee H, Ainechi S, Singh M, Ells PF, Sheehan CE, Lin J. Histological spectrum of idiopathic noncirrhotic portal hypertension in liver biopsies from dialysis patients. Int J Surg Pathol. 2015;23(6):439–46.

    Article  PubMed  Google Scholar 

  78. Bioulac-Sage P, Le Bail B, Bernard PH, Balabaud C. Hepatoportal sclerosis. Semin Liver Dis. 1995;15(4):329–39.

    Article  CAS  PubMed  Google Scholar 

  79. Jharap B, van Asseldonk DP, de Boer NKH, et al. Diagnosing nodular regenerative hyperplasia of the liver is thwarted by low interobserver agreement. PLoS ONE. 2015;10:e0120299.

    Article  PubMed  PubMed Central  Google Scholar 

  80. de Franchis R; On behalf of the Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53:762–768.

  81. Sarin SK, Gupta N, Jha SK, Agrawal A, Mishra SR, Sharma BC, et al. Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. Gastroenterology. 2010;139:1238–45.

    Article  CAS  PubMed  Google Scholar 

  82. Sarin SK, Sollano JD, Chawla YK, Amarapurkar D, Hamid S, Hashizume M, et al. Members of the APASL working party on portal hypertension. Consensus on extra-hepatic portal vein obstruction. Liver Int. 2006;26:512–9.

    Article  PubMed  Google Scholar 

  83. Romano M, Giojelli A, Capuano G, Pomponi D, Salvatore M. Partial splenic embolization in patients with idiopathic portal hypertension. Eur J Radiol. 2004;49:268–73.

    Article  PubMed  Google Scholar 

  84. Hirota S, Ichikawa S, Matsumoto S, Motohara T, Fukuda T, Yoshikawa T. Interventional radiologic treatment for idiopathic portal hypertension. Cardiovasc Intervent Radiol. 1999;22:311–4.

    Article  CAS  PubMed  Google Scholar 

  85. Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl. 2005;11:627–34.

    Article  PubMed  Google Scholar 

  86. Dumortier J, Bizollon T, Scoazec JY, Chevallier M, Bancel B, Berger F, et al. Orthotopic liver transplantation for idiopathic portal hypertension: indications and outcome. Scand J Gastroenterol. 2001;36:417–22.

    Article  CAS  PubMed  Google Scholar 

  87. Loinaz C, Colina F, Musella M, Lopez-Rios F, Gomez R, Jimenez C, et al. Orthotopic liver transplantation in 4 patients with portal hypertension and non-cirrhotic nodular liver. Hepato-Gastroenterol. 1998.

Download references

Author information

Authors and Affiliations

  1. Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, Pakistan

    Talal Khurshid Bhatti

  2. Stanford University School of Medicine, 430 Broadway, Pavilion C, 3Rd Floor, Redwood City, Palo Alto, CA, USA

    Paul Y. Kwo

Authors
  1. Talal Khurshid Bhatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Y. Kwo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

PK made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; drafted the work or revised it critically for important intellectual content; approved the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. TK made substantial contributions to the acquisition, analysis, or interpretation of data; drafted the work or revised it critically for important intellectual content; approved the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to Paul Y. Kwo.

Ethics declarations

Competing interests

The authors declare no competing interests.

Conflict of Interest

None.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhatti, T.K., Kwo, P.Y. Systemic Disease and Portal Hypertension. Curr Hepatology Rep 23, 162–173 (2024). https://doi.org/10.1007/s11901-024-00645-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-024-00645-8

Keywords

Search

Navigation